The Efficacy of Vedolizumab Versus Mesalazine in Active Ulcerative Colitis
LIN Xiaohan
BEN Teng
Abstract：Objective To explore the clinical efficacy and safety of vedolizumab and mesalazine in the treatment of active ulcerative colitis(UC).Methods A total of 105 patients with active UC who received targeted treatment in our hos-pital from January 2019 to December 2023 were selected as the subjects of this experiment and randomly divided into the vedolizumab group(53 cases)and the mesalazine group(52 cases).Patients in both groups were given conventional treatment.On this basis,the vedolizumab group was treated with vedolizumab,and the mesalazine group was treated with mesalazine.The clinical efficacy,the indicators related to intestinal mucosal harrier function,the specific concentration levels of inflammatory factors and the intestinal flora before and after treatment were observed and compared between the two groups,and the specific occurrence probability of adverse reactions was recorded.Results The total effective rate of treatment in the vedolizumab group was 94.34％,which was higher than that in the mesalazine group(80.77％)(x2=4.456,P＜0.05).After treatment,the levels of D-lactic acid,endotoxin and inflammatory factors IL-17 and IL-23 in the vedolizumab group[(4.98±1.23)μg/L,(2.26±0.92)U/mL,(206.74±15.34)pg/L,(252.93±19.43)pg/L,respectively]were lower than those in the mesalazine group[(6.25±1.87)μg/L,(3.41±1.13)U/mL,(224.89±16.56)pg/L,(280.32±20.89)pg/L,respectively](t=4.119,5.724,5.828,6.958,all P＜0.05),the levels of Lactobacillus and Bifidobacterium[(19.65±2.34)lg CFU/g,(17.34±1.98)lg CFU/g]were higher than those in the mesalazine group[(14.89±1.76)lg CFU·g-1,(14.01±1.45)lg CFU/g],and the levels of Escherichia coli and Enterococcus[(3.92±0.78)lg CFU/g,(3.71±0.56)lg CFU/g]were lower than those in the mesalazine group[(6.25±1.23)lg CFU/g,(6.05±0.89)lg CFU/g](t=11.763,9.817,11.615,16.157,all P＜0.05).During the treatment period,there was no significant difference in the incidence of ad-verse reactions between the two groups(P＞0.05).Conclusion Vedolizumab is more effective than me-salazine in treating active UC in relieving clinical symp-toms,improving intestinal mucosal barrier function and flora levels,reducing inflammatory factor levels,and has a lower incidence of adverse reactions.
Keywords：VedolizumabMesalazineColitisUlcerativeComparative Effectiveness ResearchIntestinal Mucosal Barrier FunctionInflammatory Factors
Publication Date：2024-10-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1474-1478 )